X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AUROBINDO PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AUROBINDO PHARMA DIVIS LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x 18.1 18.0 100.9% View Chart
P/BV x 3.9 5.8 67.2% View Chart
Dividend Yield % 1.6 0.4 444.4%  

Financials

 DIVIS LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
AUROBINDO PHARMA
Mar-16
DIVIS LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,4841,541 161.2%   
Low Rs918582 157.7%   
Sales per share (Unadj.) Rs142.3237.5 59.9%  
Earnings per share (Unadj.) Rs41.933.9 123.7%  
Cash flow per share (Unadj.) Rs46.340.6 114.2%  
Dividends per share (Unadj.) Rs10.002.50 400.0%  
Dividend yield (eoy) %0.60.2 249.6%  
Book value per share (Unadj.) Rs161.5120.6 133.9%  
Shares outstanding (eoy) m265.47585.17 45.4%   
Bonus/Rights/Conversions -PREF-  
Price / Sales ratio x12.04.5 267.5%   
Avg P/E ratio x40.631.3 129.6%  
P/CF ratio (eoy) x36.726.2 140.4%  
Price / Book Value ratio x10.58.8 119.7%  
Dividend payout %23.97.4 323.5%   
Avg Mkt Cap Rs m451,525621,041 72.7%   
No. of employees `0003.713.3 27.9%   
Total wages/salary Rs m3,64915,508 23.5%   
Avg. sales/employee Rs Th10,184.410,457.6 97.4%   
Avg. wages/employee Rs Th984.11,167.1 84.3%   
Avg. net profit/employee Rs Th2,998.51,491.6 201.0%   
INCOME DATA
Net Sales Rs m37,764138,961 27.2%  
Other income Rs m8481,663 51.0%   
Total revenues Rs m38,612140,624 27.5%   
Gross profit Rs m14,13832,056 44.1%  
Depreciation Rs m1,1823,926 30.1%   
Interest Rs m232,568 0.9%   
Profit before tax Rs m13,78127,225 50.6%   
Minority Interest Rs m039 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,6627,444 35.8%   
Profit after tax Rs m11,11919,820 56.1%  
Gross profit margin %37.423.1 162.3%  
Effective tax rate %19.327.3 70.7%   
Net profit margin %29.414.3 206.4%  
BALANCE SHEET DATA
Current assets Rs m30,947100,015 30.9%   
Current liabilities Rs m5,19574,759 6.9%   
Net working cap to sales %68.218.2 375.2%  
Current ratio x6.01.3 445.3%  
Inventory Days Days117107 108.7%  
Debtors Days Days85110 77.7%  
Net fixed assets Rs m17,02752,350 32.5%   
Share capital Rs m531585 90.7%   
"Free" reserves Rs m42,34167,707 62.5%   
Net worth Rs m42,87770,567 60.8%   
Long term debt Rs m58,472 0.1%   
Total assets Rs m49,684156,994 31.6%  
Interest coverage x595.011.6 5,128.0%   
Debt to equity ratio x00.1 0.1%  
Sales to assets ratio x0.80.9 85.9%   
Return on assets %22.414.3 157.3%  
Return on equity %25.928.1 92.3%  
Return on capital %32.237.7 85.3%  
Exports to sales %85.351.0 167.0%   
Imports to sales %22.918.8 121.6%   
Exports (fob) Rs m32,19870,927 45.4%   
Imports (cif) Rs m8,65426,193 33.0%   
Fx inflow Rs m32,27071,015 45.4%   
Fx outflow Rs m8,77528,799 30.5%   
Net fx Rs m23,49642,216 55.7%   
CASH FLOW
From Operations Rs m10,37917,596 59.0%  
From Investments Rs m-4,135-13,801 30.0%  
From Financial Activity Rs m-6,241-198 3,147.5%  
Net Cashflow Rs m33,597 0.1%  

Share Holding

Indian Promoters % 52.0 54.1 96.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.0 148.4%  
FIIs % 19.0 27.7 68.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.2 168.6%  
Shareholders   31,796 69,601 45.7%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS